Skip to content
You can now search across every topic, entity and event.What's new
Longwall Ventures
OrganisationGB

Longwall Ventures

Oxford deeptech VC writing £500k-£2m cheques; Fund 1 backed OrganOx, sold to Terumo for $1.5bn.

Longwall Ventures, the Oxford deeptech investor whose Fund 1 turned OrganOx into a $1.5bn Terumo takeover in 2025, took a £50m cornerstone commitment from the British Business Bank into Fund 4 on 27 May 2026.

Last refreshed: 22 July 2026 · Appears in 1 active topic

Key Question

Is Longwall Ventures' 19x OrganOx exit a repeatable formula or a once-in-a-decade outlier?

Timeline for Longwall Ventures

#12 20 Jul
#12 15 Jul
#11 13 Jul
#9 22 Jun
View full timeline →

Background

The British Business Bank anchored Longwall's fourth fund with a £50m cornerstone investment on 27 May 2026, delivered through its Enterprise Capital Funds programme; the fund was chasing a £100m close and stood at £86.2m when the commitment landed. Fund 4 is aimed at 14 to 16 early companies spanning life sciences, defence, clean energy and advanced manufacturing.

Set up in Oxford between 2008 and 2011, the firm's defining result remains Fund 1's stake in OrganOx: the university spinout's liver-perfusion technology sold in 2025 to Japan's Terumo for $1.5bn, seventeen years after OrganOx was founded and a 19.2x return on the Bank's original stake, the largest sum ever paid for an Oxford University spinout.

Longwall calls its niche the 'tier gap', the stretch between a university's proof-of-concept grant and an institutional Series A round where deeptech ventures most often run out of money. Bank figures published on 2 July 2026 gave that thesis fresh weight: university spinout equity deals fell 33% by number and 51% by value across 2025, with more than a third of rounds closing under £500,000, evidence the Bank cites for renewing its Longwall commitment rather than assuming the gap will close unaided.

Common Questions
What is the Longwall Ventures OrganOx exit and why does it matter for UK deeptech?
Longwall's Fund 1 backed OrganOx, which was sold to Terumo for $1.5bn in 2025, a 19.2x return on the British Business Bank's original capital and the largest-ever Oxford University spinout acquisition.Source: IT Pro / Oxford University
How much has the British Business Bank committed to Longwall Ventures and for what purpose?
The British Business Bank has committed £50m as a cornerstone investor in Longwall Fund 4, which targets £100m to back 14-16 early-stage deeptech firms writing £500k-£2m cheques.Source: IFA Magazine
What sectors does Longwall Ventures invest in?
Longwall writes cheques into early-stage UK deeptech across advanced manufacturing, clean energy, defence and life sciences, typically filling the gap between university proof-of-concept grants and institutional Series A rounds.Source: IT Pro
Why does the UK deeptech funding gap keep widening in 2026?
British Business Bank data published 2 July 2026 showed university spinout equity deals down 33% by count and 51% by value in 2025, with over a third of rounds closing below £500,000, exactly the tier gap Longwall's funds are designed to bridge.Source: British Business Bank tracker
Source Material